RESUMO
Henoch-Schonlein purpura (HSP) is an acute systemic form of vasculitis that has been associated with a number of viral and bacterial infections. Described here are the cases of two children with invasive meningococcal disease who presented with clinical and laboratory findings typical of HSP. Meningococcal infection may have been the trigger for the manifestation of HSP in these patients.
Assuntos
Vasculite por IgA/microbiologia , Infecções Meningocócicas/complicações , Bacteriemia/complicações , Pré-Escolar , Feminino , Humanos , Vasculite por IgA/tratamento farmacológico , Vasculite por IgA/imunologia , Imunoglobulinas Intravenosas/uso terapêutico , Masculino , Infecções Meningocócicas/imunologiaRESUMO
The cases of 2 siblings with cat scratch disease are described who presented with symptoms suggestive of acute febrile gastroenteritis. The first patient, a 7.5-y-old girl, developed mesenteric lymphadenitis, hepatosplenic granulomas and osteolytic bone lesions only late in the course of her protracted illness. Her 3-y-old brother had a shorter, self-limited illness without complications. Cat scratch disease is often unrecognized and the full spectrum of its clinical manifestations remains to be investigated.
Assuntos
Doença da Arranhadura de Gato/diagnóstico , Gastroenterite/etiologia , Doença Aguda , Criança , Pré-Escolar , Feminino , Febre/etiologia , Humanos , Masculino , Núcleo Familiar , Testes SorológicosRESUMO
UNLABELLED: A 5-month-old girl presented with persistent dry cough, intermittent pyrexia and lymphocytosis, arthralgia, nodular skin lesions and an erythema nodosum-like rash. Chest CT scan revealed bilateral pulmonary infiltration. On the grounds of clinical and imaging findings, Gallium scanning and open lung biopsy were performed, providing evidence compatible with sarcoidosis. CONCLUSION: Despite what has previously been reported, sarcoidosis in infancy can present with pulmonary symptomatology.
Assuntos
Sarcoidose Pulmonar/diagnóstico , Feminino , Humanos , LactenteRESUMO
Ketotifen was administered orally, for 3 months, to 40 children aged 3-14 years with chronic extrinsic asthma of moderate severity in a double-blind placebo-controlled study. A significant clinical improvement with concomitant reduction of antiasthmatic drugs was found in the group receiving the active drug compared with the placebo group (p less than 0.05). The continued administration of ketotifen in an open study to a group of 21 children comprised of patients belonging to both groups (active-placebo) for a period of 15-18 months resulted in disappearance of symptoms in 10 children (47.6%) and moderate improvement in 7 (33.3%).
